11/13/2025
🌟 Major Update in Women’s Health 🌟
We’re thrilled to share that the Food & Drug Administration (FDA) is making historic changes to hormone replacement therapy (HRT) for menopause — paving the way for better access, clearer options, and smarter conversations.
💡 What’s new?
The FDA is requesting removal of the longstanding “black box” warning on many HRT products. The warnings being removed include those about cardiovascular disease, breast cancer, and dementia — for many of the affected therapies.
Importantly, the FDA emphasizes this doesn’t mean HRT is risk-free. Working with your provider to assess the right option for you remains crucial.
If you’re navigating perimenopause or menopause — struggling with hot flashes, night sweats, mood changes, sleep disruption, bone loss, etc. — this update might open new conversations with your healthcare provider.
🔍 Important to remember
HRT is not a one-size-fits-all. The form of therapy (systemic vs localized), timing of initiation, individual health history and risk factors all matter.
Some warnings remain: for example, systemic estrogen-alone products still carry warnings about endometrial cancer.
Starting early (within ~10 years of menopause onset or before age 60) tends to show the best risk-benefit balance.
👉 What you can do
✨Ask about: timing (are you within the 10‐year window?), risks based on your individual health, types of therapy (systemic vs local), and benefits you might gain.
✨Make sure your decision is personalized — don’t rely on outdated broad warnings.
✨Stay informed and ask for the latest evidence and guidelines.
Here’s to empowering women’s health — better choices, clearer options, and more confidence in the journey through menopause. 💪✨
✨ Call to schedule a consultation to discuss your HRT options! ✨
📞 870-232-0900
